Cisatracurium Besylate

Only a few weeks after the FDA recognized a shortage of Adderall , another crucial drug is in low supply, this time the antibiotic amoxicillin. According to the American Society of Health System Pharmacists’ (AHSP) drug shortage list, three manufacturers are posting shortages of the oral version of the drug. The list includes Hikma Pharmaceuticals, Teva and Sandoz, which are reporting low supplies of multiple dosage amounts. The companies did not post a reason for the shortages. The ASHP report states that Rising Pharmaceuticals still has tablets available, and Aurobindo did not provide any information. Teva estimates that some stock will become available this month, and chewable doses will be available in November. An FDA spokesperson told Endpoints News : The FDA is aware of some intermittent supply interruptions of amoxicillin products in the U.S, and are currently working with the approved manufacturers. The FDA’s Drug Shortage Staff regularly work with manufacturers to evaluate the entire supply chain of drug products to help prevent or reduce the impact of a drug shortage. If a shortage cannot be prevented, we would provide a posting of availability for all approved products. Endpoints did reach out to the listed companies but did not receive a response by press time and will update the story accordingly. Michael Ganio, senior director of pharmacy practice and quality at ASHP, told Endpoints that none of the producers are seeing disruptions in the manufacturing process which is where shortages tend to occur. Ganio also noted that it is hard to tell at this point if this is a true supply problem or just a surge in demand for amoxicillin. He notes that there has been an increase in prescriptions for the drug as some practitioners turn to antibiotics even when it may not be the most appropriate course of action. Ganio also added that the supply issue may not last long, as Teva is planning to return to stock, and this situation means that the companies are not keeping a lot of product on the shelves. Ganio said: “We saw this early Covid were especially in New York City but also New Orleans and some areas of Michigan had problems getting injectable opioids, sedatives, neuromuscular blockers to take care of patients that were on the ventilators and it was just a matter of the traditional way of managing a shortage at a wholesaler level or even the manufacturer level is to put in limited allocations so that they can purchase more. The only problem with that model, it protects the supply when there’s a limited supply, but when it’s a surging demand, you know those allocations are typically based on historical purchases, so they’re not an accurate measure of what’s needed on the front lines. So, between having allocations in place that are based on historical demand, this is not matching historical trends.” He notes that there are more alternatives for amoxicillin than with other drugs that are facing shortages, such as Adderall. Matthew Christian, director of supply chain insights at US Pharmacopeia, told Endpoints that there can be a serious risk when it comes to shortages in antibiotics. “One of the concerns about antibiotics, in particular, is shortage events. The market demands got to be met and sometimes, particularly in low- or in middle-income countries, that market demand is met by falsified or substandard medications. And, you know, taking the incorrect amount or failure to take the antibiotics as they are designed can increase AMR (antimicrobial resistance) threats,” Christian said to Endpoints. Christian also noted that the recent shortages of generic Adderall and amoxicillin are occurring more in oral forms of medicine than injectables, which is a trend that has been occurring for the past five years and that companies have been taking extra steps to resolve.